A Phase III, Parallel-Group, Prospective, Randomized, Double-blind, Active-controlled, Two- Arm Study to Evaluate the Immunogenicity, Safety, and Tolerability of the MVC-COV1901 Compared to AZD1222 in Adult of 18 Years and Above
Latest Information Update: 26 Oct 2023
At a glance
- Drugs MVC COV1901 (Primary) ; Adjuvants; AZD 1222
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Medigen Vaccine Biologics
Most Recent Events
- 20 Oct 2023 Status changed from active, no longer recruiting to completed.
- 13 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 23 Aug 2022 Planned primary completion date changed from 1 Sep 2022 to 1 Nov 2022.